07:18 AM EDT, 09/29/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Monday its potential HER2-positive breast cancer therapy Enhertu showed "highly statistically significant" and "clinically meaningful" improvement in meeting its primary endpoint of invasive disease-free survival compared with the standard of care in an interim analysis of an ongoing phase 3 trial.

The trial sample was composed of patients with high risk early breast cancer with residual invasive disease in the breast or axillary lymph nodes following neoadjuvant therapy, the company said.

The drug's safety profile in the trial was consistent with its known profile with no new safety concerns identified, the company said.

The company said overall survival rates will be assessed at a subsequent analysis.

Enhertu was discovered by Japan's Daiichi Sankyo and is being jointly developed and commercialized by AstraZeneca ( AZN ) and Daiichi Sankyo.

AstraZeneca ( AZN ) shares were up 1.1% in recent premarket activity.